MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tremors: Treatment"

  • 2024 International Congress

    Suvecaltamide Metabolites Are CaV3 Modulators and Contribute to Pharmacological Effect

    E. Brigham, W. Zeng, N. Shanks, M. Lee (Palo Alto, USA)

    Objective: To determine the potency-concentration relationships and combined pharmacological effects for suvecaltamide and its 2 active metabolites (JZZ05000034=M01, JZZ05000035=M02; total active moiety [TAM]). Background: T-type…
  • 2024 International Congress

    SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor

    P. Lewitt, H. Jinnah, R. Pahwa, A. Ellenbogen, R. Kumar, TM. Lieu, B. Hersh, R. Chuang, C. Vaudreuil, Z. Berger, D. Arkilo, SH. Kuo (Bloomfield, USA)

    Objective: KINETIC2 is a multicenter, randomized, placebo-controlled, dose-response Ph2b study evaluating SAGE-324/BIIB124 for treatment of essential tremor (ET). Background: ET is a common movement disorder1,2…
  • 2024 International Congress

    Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor

    N. Shanks, S. Markova, R. Mukkavilli, L. Tan, M. Lee, E. Brigham (Palo Alto, USA)

    Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…
  • 2024 International Congress

    Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study

    S. Markova, M. Baladi, M. Lee, C. Chen (Palo Alto, USA)

    Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…
  • 2024 International Congress

    The Fazekas scale score and the occurrence of adverse events after MRgFUS thalamotomy, is there a relationship?

    C. Ribacoba Díaz, A. Fernández Revuelta, M. Yus Fuertes, C. Pérez García, A. Trondin, E. López Valdés, R. García-Ramos García (Madrid, Spain)

    Objective: To analyse whether the score on the Fazekas scale (FS) correlates with an increased risk of adverse effects (AEs) after unilateral magnetic resonance-guided focused…
  • 2023 International Congress

    Outcomes of Focused Ultrasound Thalamotomy in Tremor Syndromes

    J. Peters, J. Maamary, K. Kyle, N. Olsen, L. Jones, S. Bolitho, Y. Barnett, B. Jonker, S. Tisch (Darlinghurst, Australia)

    Objective: To report on the outcomes between tremor subtypes, Essential Tremor (ET), Dystonic Tremor (DT) and Parkinson Disease Tremor (PDT), following a unilateral Magnetic Resonance…
  • 2023 International Congress

    The added value of accelerometric monitoring during thalamotomy

    A. Smid, M. Oterdoom, R. Pauwels, K. Tamasi, J. Elting, A. Absalom, T. van Laar, M. van Dijk, G. Drost (Groningen, Netherlands)

    Objective: To quantify the clinical changes in tremor during the different stages of thalamotomy, and to investigate the relationship between intraoperative findings and clinical outcome.…
  • 2023 International Congress

    The feasibility of MRI guided focused ultrasound for posttraumatic tremor with prior hemicraniotomy and skull defect

    J. Maamary, J. Peters, Y. Barnett, B. Jonker, S. Tisch (Darlinghurst, Australia)

    Objective: To assess the feasibility of MRgFUS lesioning in the context of prior hemicraniotomy Background: Targeted stereotactic lesioning, using MRgFUS, is an effective treatment option…
  • 2023 International Congress

    Improved Tremor Response to Focused Ultrasound Thalamotomy

    J. Holcomb, R. Chopra, F. Feltrin, M. Elkurd, R. El-Nazer, L. Mckenzie, P. O’Suillebhain, J. Maldjian, W. Dauer, B. Shah (Dallas, USA)

    Objective: This study sought to determine if, when using four tract tractography (FTT) to target the decussating and non-decussating dentatorubrothalamic tracts (DRTTs), essential tremor (ET)…
  • 2023 International Congress

    Anti-tremor efficacy of Nabiximols (JZP378) in a rat Model of essential tremor

    S. Loomis, E. Samoylenko, D. Virley, A. Mccreary (Cambridge, United Kingdom)

    Objective: To assess the effect of acute and subchronic oral administration of nabiximols (JZP378), a complex botanical cannabinoid drug mixture with Δ9-tetrahydrocannabinol (THC) and cannabidiol…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 17
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley